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ABSTRACT 
Molecular dimerization of antiprotozoal compounds may be used to overcome drug resistance. Huprines are a class of 4-aminoquinoline 
derivatives endowed with trypanocidal and antimalarial activities. We have synthesized a series of dimers of (+)-(7R,11R)-huprine Y with 
linkers of different length and chemical nature and evaluated their activity against cultured bloodstream forms of Trypanosoma brucei and 
Plasmodium falciparum, and their cytotoxicity against rat myoblast L6 cells. We also assessed their brain permeability, a requirement in drugs 
aimed at treating the late stages of infections with these parasites. Most of the new dimers exhibit more potent trypanocidal activity than the 
parent huprine Y, with IC90 values in the submicromolar range and better selectivity indices (up to 38). They have a predicted ability to cross 
the blood-brain barrier, but seem to be devoid of significant antimalarial activity. Bis(+)-huprines therefore emerge as interesting brain 
permeable trypanocidal leads.
——— 
 Corresponding author. Tel.: +34-934024533; fax: +34-934035941; e-mail: dmunoztorrero@ub.edu (D. Muñoz-Torrero) 
In the last few years, implementation of prevention and 
control measures has significantly reduced the burden of tropical 
protozoan diseases such as human African trypanosomiasis 
(HAT or sleeping sickness) and malaria. However, approximately 
70 million people remain at risk of HAT, and in the case of 
malaria, half of the world’s population live in countries where the 
disease is endemic. Thus, these parasitic infections continue to 
pose a serious health threat, especially in developing regions.
1,2
 
The causative agents of HAT and malaria are the single-celled 
parasites Trypanosoma brucei gambiense or T. brucei 
rhodesiense, and several species of the genus Plasmodium, 
amongst which, P. falciparum is the most common and deadly. 
The parasites are transmitted through the bite of infected insects, 
namely Glossina flies (tsetse flies) for HAT and Anopheles 
mosquitoes for malaria.  
In HAT, following an initial hemolymphatic phase, parasites 
can cross the blood‒brain barrier (BBB) and infect the central 
nervous system (CNS), leading to severe neurological symptoms. 
Without treatment, death is inevitable when the disease has 
reached this late stage. In malaria, the parasites multiply initially 
in the liver, and then in the bloodstream. In severe cases, they can 
become sequestered within brain capillaries, particularly in 
children, causing the so-called cerebral malaria, frequently with 
fatal consequences. 
Current options to reduce the burden of HAT and malaria are 
far from ideal.
3-5
 There is no licensed vaccine for either infection, 
with vector control and public health measures being the main 
means of prevention. Currently registered drugs are problematic, 
with toxicity and resistance being major problems. For example, 
although five drugs have been approved for the treatment of HAT 
(pentamidine, suramin, melarsoprol, nifurtimox and eflornithine), 
their activity can be stage and/or species specific, they display a 
range of toxic side effects, and require strict and complicated 
parenteral administration regimens.
6
 This type of specialized 
infrastructure is often unavailable in the poor rural settings where 
HAT is endemic. Drug resistance continues to emerge and 
undermine clinical effectiveness. Increased resistance has been 
observed for the trypanocidal agent melarsoprol. In the case of 
malaria, chloroquine is no longer widely effective and rising 
resistance against the current front line drug artemisinin is a 
potential threat to global health. Overall, there is an acute need to 
develop novel drugs for HAT and malaria that can circumvent 
the limitations of existing therapies. 
Several approaches have been proposed to speed up the 
antiprotozoal drug pipeline. These include high-throughput 
screening of large compound libraries, new strategies to 
functionally validate novel druggable targets involved in key 
steps of the parasite life-cycle,
7-10
 or the simultaneous inhibition 
of two or more key biological targets with combination therapies 
or multitarget-directed ligands.
11-13
 Increasingly,  the search for 
novel antiprotozoal agents also involves the repositioning of 
existing drugs registered for other applications
14
 or the synthesis 
of new chemical entities endowed with antiprotozoal activity.
15-17 
 
In recent years, new compounds bearing the 4-amino-7-
chloroquinoline core of chloroquine, or other aminoquinoline 
moieties, have been assessed as novel trypanocidal or 
antimalarial agents, or as dual agents endowed with both 
activities.
18-21
 The development of single molecules that have 
potency against different protozoan diseases (such as HAT and 
malaria) has been regarded as an feasible approach, with 
potential economic savings.
22
 We recently reported that the 
aminoquinoline derivatives huprines, a structural class initially 
developed as inhibitors of the enzyme acetylcholinesterase, are 
moderately effective and selective trypanocidal agents, with 
some also being active against a chloroquine-resistant strain of P. 
falciparum.
23,24
 In particular, the 4-amino-7-chloroquinoline 
derivative 1 (huprine Y, Scheme 1) exhibited the lowest IC50 
value of the series against T. brucei (IC50 = 0.61 µM; IC90 = 2.94 
µM), with one of the best selectivity indices over rat myoblast L6 
cells (SI = 13) among the entire set of tested huprines.
23
 
Molecular dimerization of compounds with known 
antiprotozoal activity constitutes a strategy that can be used to 
overcome drug resistance.
25
 This approach has proven successful 
for dimers of 4-aminoquinolines, in which the two constituting 
units were connected through linkers of different length or 
containing different functional groups.
26-29
 
Here, we report the synthesis of dimers of huprine Y, in which 
the two huprine moieties have been connected through 
oligomethylene linkers of different length, or with a p-phenylene-
bis(methylene) tether. To this end, enantiopure (+)-(7R,11R)-
huprine Y [(7R,11R)-1, Scheme 1], the least active enantiomer in 
terms of acetylcholinesterase inhibition activity,
30-32
 has  been 
used. The dimeric bis(+)-huprines have been tested against 
cultured bloodstream forms of T. brucei and P. falciparum, and 
their cytotoxicity against mammalian cells and brain permeability 
has been assessed. 
The synthesis of hexa-, octa-, deca-, and dodeca-methylene 
linked bis-huprines (+)-2a‒d and the p-phenylene-
bis(methylene)-linked bis-huprine (+)-2e was carried out by 
reaction of 2 equivalents of (+)-(7R,11R)-huprine Y with 1 
equivalent of the corresponding α,ω-dihaloalkane, using KOH as 
the base in DMSO at room temperature for three days (Scheme 
1). After silica gel column chromatography purification, bis(+)-
huprines (+)-2a‒d were obtained in moderate yields (21‒50% 
yields, whereas (+)-2e was obtained in a lower yield (11%) along 
with the byproduct resulting from the monoalkylation of (+)-1 
(12% yield). 
Bis-huprines (+)-2a‒e were converted into the corresponding 
dihydrochlorides for their chemical characterization (specific 
rotation, melting point, IR, 
1
H and 
13
C NMR, HRMS, and 
elemental analysis) and biological profiling.
33
 
 
 
 
Scheme 1. Synthesis of bis-huprines (+)-2a‒e. 
 
Bis-huprines (+)-2a‒e were first tested in vitro against 
cultured bloodstream forms of T. brucei. All of the bis-huprines 
exhibited IC50 values in the range 0.50‒0.89 µM. Their IC90 
values of around 1 µM (0.73‒1.09 µM) (Table 1), were 
significantly lower than the parent huprine Y (IC90 = 2.94 µM). 
Given the narrow range of potencies of the different bis-huprines, 
the length of the linker or the presence of a benzene ring within 
the linker do not seem to have a strong influence on the 
trypanocidal activity of bis(+)-huprines. Thus, the increased 
trypanocidal potency of bis-huprines, relative to huprine Y, might 
be ascribed to the dimerization strategy, even though the 
mechanisms responsible for inhibition of trypanosome growth or 
for the enhanced activity are not known. 
Bis-huprines (+)-2a‒e were also evaluated against the 
chloroquine-resistant K1 strain of P. falciparum. Even though 
some huprines have been reported to exhibit moderately potent 
antiplasmodial properties,
23
 huprine Y did not exhibit significant 
activity (IC50 > 10 µM). Huprine Y bears the 4-amino-7-
chloroquinoline moiety, thought to be an antimalarial 
pharmacophore responsible for inhibition of haem 
dimerization.
20,34
 Since dimerization of other 4-aminoquinoline 
compounds increased antiplasmodial potency and/or overcame 
the chloroquine resistance mechanism,
26-29
 we hypothesized that 
dimerization of huprine Y to bis-huprines (+)-2a‒e might also 
enhance activity. However, no noticeably increased 
antiplasmodial potency was observed for the dimeric compounds, 
which exhibited IC50 values > 5 µg/mL (i.e. > 6‒7 µM), much 
higher than that of artemisinin (IC50 = 91 nM) used in this assay 
as a positive control. The improvement of potency against 
chloroquine resistant strains of P. falciparum of other bis(4-
aminoquinoline) derivatives relative to the corresponding 
monomeric compounds has been ascribed mainly to the doubling 
of the number of protonatable nitrogen atoms in the dimers, 
which might lead to more efficient trapping in the acidic 
digestive vacuole of the parasite and prevention of heme 
polymerization.
25,29
 The failure of bis-huprines to show 
antiplasmodial activity might be indicative of the fact that these 
compounds cannot hit the biological target of chloroquine and 
other 4-aminoquinoline derivatives despite their structural 
similarity. Indeed, we have recently found that the parent huprine 
Y, unlike chloroquine, shows no inhibition of β-haematin 
formation, whereas several huprine analogues that possess 
antiplasmodial activity are effective inhibitors of β-haematin 
formation (unpublished results). 
 
Table 1 
Trypanocidal and cytotoxic activity of bis-huprines (+)-2a‒ea 
Compd T. brucei 
IC50 µM 
T. brucei 
IC90 µM 
L6 cells 
IC50 µM 
SIb 
(+)-2a 0.89 ± 0.02 1.09 ± 0.01 1.61 ± 0.07 1.8 
(+)-2b 0.52 ± 0.01 0.74 ± 0.02 4.92 ± 0.15 9.5 
(+)-2c 0.50 ± 0.01 0.73 ± 0.01 7.71 ± 0.70 15.4 
(+)-2d 0.76 ± 0.03 0.99 ± 0.05 28.5 ± 2.9 37.5 
(+)-2e 0.57 ± 0.02 0.75 ± 0.02 16.1 ± 0.3 28.2 
huprine Y, 1 0.61 ± 0.03c 2.94 ± 0.20c 7.80 ± 0.47c 12.8 
a In vitro activity against bloodstream form of T. brucei (pH 7.4) and rat 
myoblast L6 cells expressed at the concentration that inhibited growth by 
50% (IC50) and 90% (IC90, for trypanocidal activity). Data are the mean of 
triplicate experiments ± SEM. 
b SI: Selectivity index is the ratio of cytotoxic to trypanocidal IC50 values. 
c Taken from ref. 23. 
 
The cytotoxicity of bis-huprines was assessed in vitro using 
rat skeletal myoblast L6 cells. These compounds displayed a 
modest toxicity against the mammalian cells, exhibiting IC50 
values in the range 1.6‒28.5 µM (Table 1). A clear structure-
cytotoxicity trend was found, with cytotoxicity decreasing with 
increased tether length and with the presence of a benzene ring 
within the linker. Thus, the dodecamethylene-linked bis-huprine 
(+)-2d was found to be 18-, 6-, and 4-fold less cytotoxic than the 
hexa-, octa-, and deca-methylene counterparts (+)-2a, (+)-2b, and 
(+)-2c, respectively, whereas the p-phenylene-bis(methylene)-
linked bis-huprine (+)-2e was 10-fold less cytotoxic than the 
oligomethylene-linked bis-huprine with a similar tether length, 
(+)-2a. Thus, the longest homologue (+)-2d and the p-phenylene-
bis(methylene)-linked bis-huprine (+)-2e displayed the highest 
selectivity indices for trypanocidal over cytotoxic activity (SI = 
37.5 and 28.2, respectively). 
Permeability across the BBB is a necessary condition for drug 
candidates against HAT that are to be effective against late-stage 
disease, when the CNS is invaded by the parasite. The BBB 
permeability of bis-huprines (+)-2a‒e was assessed in vitro 
through the widely used parallel artificial membrane permeability 
assay (PAMPA-BBB), using a lipid extract of porcine brain as 
the artificial membrane.
35
 Assay validation was performed by 
comparing the experimentally observed permeabilities [Pe (exp)] 
of fourteen marketed drugs with the permeabilities reported in the 
literature [Pe (lit)], which provided a good linear correlation: Pe 
(exp) = 1.4974 Pe (lit) ‒ 0.8434 (R
2
 = 0.9428). Taking into 
account this equation and the limits established by Di et al.,
35
 
three ranges of BBB permeation were established: high BBB 
permeation (CNS+) for those compounds with Pe (10
‒6
 cm s
‒1
) > 
5.1; low BBB permeation (CNS‒) for those compounds with Pe 
(10
‒6
 cm s
‒1
) < 2.1; and uncertain BBB permeation (CNS±) for 
those compounds with 5.1 > Pe (10
‒6
 cm s
‒1
) > 2.1. All the bis-
huprines exhibited permeabilities clearly above the threshold 
established for high BBB permeation (Table 2), even though they 
seem to be less permeable than monomeric huprine Y. This may 
arise because they are dibasic compounds and will mostly be in 
the diprotonated form, whereas monomeric huprine, with only 
one basic nitrogen atom, will be monoprotonated under the assay 
conditions. 
Table 2 
BBB predicted permeabilities of bis-(+)-huprines (+)2a‒d and 
parent huprine Y 
Compd Pe (10
‒6 cm s‒1)a Prediction 
(+)-2a 11.1 ± 0.3 CNS+ 
(+)-2b 13.9 ± 1.0 CNS+ 
(+)-2c 8.7 ± 1.5 CNS+ 
(+)-2d 17.4 ± 0.7 CNS+ 
(+)-2e 8.3 ± 0.6 CNS+ 
huprine Y, 1 23.8 ± 2.7b CNS+ 
a Values are expressed as mean ± SD of three independent experiments. 
b Taken from ref. 32. 
In summary, we report the synthesis of a series of dimeric 
bis(4-aminoquinoline) derivatives, which are composed of two 
units of (+)-(7R,11R)-huprine Y connected through 
oligomethylene linkers of different length or a p-phenylene-
bis(methylene) linker. We also describe the assessment of the 
different bis(+)-huprines on the growth of bloodstream forms of 
T. brucei and P. falciparum, and of rat skeletal myoblast L6 cells, 
as well as their BBB permeability. All of the bis(+)-huprines 
exhibited potent trypanocidal activity, with IC50 and IC90 values 
in the submicromolar range. However, they did not exhibit 
significant antiplasmodial activity. As trypanocidal agents, 
bis(+)-huprines are more potent than monomeric huprine Y and 
some of them, particularly the dodecamethylene- and p-
phenylene-bis(methylene)-linked dimers (+)-2d and (+)-2e, are 
less cytotoxic and, hence, more selective for T. brucei over rat L6 
cells growth inhibition than huprine Y. All the bis(+)-huprines 
have been predicted to have the ability to cross the BBB, thereby 
being potentially useful for the treatment of late-stage HAT. 
Overall, bis(+)-huprines (+)-2d and (+)-2e emerge as interesting 
lead compounds for further trypanocidal drug discovery 
endeavours. 
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